aptamer


Also found in: Medical, Wikipedia.

aptamer

(ˈæptəmə)
n
an artificially created molecule of DNA or RNA
References in periodicals archive ?
US-based aptamer discovery and development company Base Pair Biotechnologies, Inc has completed a USD 3.
Saugatuck Therapeutics has acquired an exclusive licence from Yale University through Immunova for use of the NLG platform to deliver DNA aptamers and certain aptamer-based combination products.
When the drug is present in the bloodstream, the aptamer changes shape, which an electric sensor detects.
2,3) The term aptamer can also design a peptide with protein-binding properties; however, here we will only focus on oligonucleotide molecules.
Comparison of the secondary structures of our isolated aptamers and aptamer A10 obtained by protein SELEX showed similar stem-loop structures which could be responsible for the recognition of PSMA on LNCap cell surface.
Numerous experiments with aptamer selection demonstrated that aptamers can be obtained for proteins, polysaccharides, viruses and a wide variety of other targets [3].
8) Our previous work reported a DNA aptamer ZE2 could block HCV E2 from binding the CD81 receptor and the infection to human hepatocytes.
Taking advantage of the changes in secondary structure of a DNA aptamer upon binding to a small molecule like a drug, Ferguson et al.
Tokyo, Aug 15, 2013 - (JCN Newswire) - Fujitsu Limited today announced that Fujitsu Laboratories Limited, its wholly owned subsidiary, has decided to spin off its long-cultivated aptamer technology so that external resources can be employed to foster its commercialization.
However, the achievement of Macugen has given a boost to the aptamer field.
Researchers have also synthesised a molecule, called an RNA aptamer, that latches onto the carcinogenic protein and targets it for destruction, significantly reducing its presence in cells in the laboratory derived from cervical cancers.
Regado Biosciences, which specialises in the development of controllable aptamer drug systems, said it would spend the bulk of the new capital to support the Phase 3 development of its lead programme REG1 for use in percutaneous coronary intervention (PCI).